| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
Purity: Content: 35.80%
| Targets |
(Rac)-sn-Glycerol 3-phosphate is an a-site substrate analogue. It binds to the a-site and strongly inhibits the reaction rate of indole and nucleophilic indole analogues with E(AA). It serves as a precursor for the biosynthesis of triglycerides and phospholipids. It is a substrate for glycerol-3-phosphate dehydrogenase in the glycerophosphate shuttle.
|
|---|---|
| ln Vitro |
In vitro, (Rac)-sn-Glycerol 3-phosphate is used as a substrate in enzymatic assays involving glycerol-3-phosphate dehydrogenase and related metabolic research applications. It is an a-site substrate analogue that binds to the a-site and inhibits the reaction rate of indole and nucleophilic indole analogues with E(AA). It is used in biochemical and metabolic studies to explore pathways of energy production, lipid storage, and membrane synthesis.
|
| ln Vivo |
There are no in vivo applications for (Rac)-sn-Glycerol 3-phosphate as a therapeutic agent. It is a research chemical used in biochemical and metabolic studies.
|
| Enzyme Assay |
The in vitro enzyme assay for (Rac)-sn-Glycerol 3-phosphate involves measuring its activity as a substrate for glycerol-3-phosphate dehydrogenase. The enzyme catalyzes the oxidation of glycerol 3-phosphate to dihydroxyacetone phosphate, and the reaction is monitored by measuring the reduction of NAD⁺ to NADH. The compound is also used as an a-site substrate analogue in binding studies.
|
| Cell Assay |
There are no standard in vitro cell-based assays for (Rac)-sn-Glycerol 3-phosphate as it is a metabolic intermediate and research chemical, not a cell-permeant probe or drug. Its use is limited to biochemical applications.
|
| Animal Protocol |
There are no in vivo animal experimental protocols for (Rac)-sn-Glycerol 3-phosphate as it is not a drug or in vivo probe. It is a research chemical for biochemical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (Rac)-sn-Glycerol 3-phosphate are not characterized as it is not a drug. It is a research chemical. For storage, it should be kept at room temperature.
|
| Toxicity/Toxicokinetics |
No toxicity data for (Rac)-sn-Glycerol 3-phosphate are available. As a research chemical, it should be handled with standard laboratory safety precautions. It is not for human or veterinary use.
|
| References | |
| Additional Infomation |
Glyceryl-1-phosphate is a glycerol monophosphate with its phosphate group located at the 1-position. It is a metabolite found in both humans and algae. It is the conjugate acid of glycerol-1-phosphate (2-). Glyceryl-3-phosphate is a metabolite found in or produced by Escherichia coli (K12 strain, MG1655 strain). Glyceryl-3-phosphate has also been reported to exist in fruit flies, peppers, and other organisms with relevant data.
(Rac)-sn-Glycerol 3-phosphate is a key intermediate in lipid metabolism and glycolysis. It serves as a precursor for triglyceride and phospholipid biosynthesis. It is used in biochemical and metabolic studies. Its CAS number is 57-03-4. |
| Molecular Formula |
C3H9O6P
|
|---|---|
| Molecular Weight |
172.0737
|
| Exact Mass |
172.014
|
| CAS # |
57-03-4
|
| Related CAS # |
(Rac)-sn-Glycerol 3-phosphate sodium;1555-56-2
|
| PubChem CID |
754
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
1.738 g/cm3
|
| Boiling Point |
485.5ºC at 760 mmHg
|
| Flash Point |
247.4ºC
|
| Source |
Endogenously produced metabolite
|
| LogP |
-2.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
129
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(=O)(O[H])(O[H])OC([H])([H])C([H])(C([H])([H])O[H])O[H]
|
| InChi Key |
AWUCVROLDVIAJX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H9O6P/c4-1-3(5)2-9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
|
| Chemical Name |
2,3-dihydroxypropyl dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~175 mg/mL (~1017.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8116 mL | 29.0579 mL | 58.1159 mL | |
| 5 mM | 1.1623 mL | 5.8116 mL | 11.6232 mL | |
| 10 mM | 0.5812 mL | 2.9058 mL | 5.8116 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA